Outlook Therapeutics
OTLK
87 hedge funds and large institutions have $51.1M invested in Outlook Therapeutics in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 7 closing their positions.
72% more capital invested
Capital invested by funds: $29.7M → $51.1M (+$21.4M)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
6% more funds holding
Funds holding: 82 → 87 (+5)
0.04% more ownership
Funds ownership: 0.53% → 0.57% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.57M |
| 2 |
State Street
Boston,
Massachusetts
|
+$998K |
| 3 |
Squarepoint
New York
|
+$343K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$250K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$507K |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$350K |
| 3 |
VF
Vista Finance
Clayton,
Missouri
|
-$237K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$107K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$98.8K |
OTLK Hedge Fund Activity: Q2 2023 in Review
87 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2023, worth a combined $51.1M — up 72% from $29.7M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new OTLK positions and 7 closed out — a net gain of 5 holders — while 31 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $1.57M. The largest seller was Millennium Management, cutting an estimated $507K.
- 87 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2023, up from 82 in Q1 2023.
- Funds reported $51.1M of Outlook Therapeutics stock for Q2 2023, up 72% quarter-over-quarter.
- 12 funds opened new Outlook Therapeutics positions in Q2 2023 and 7 closed out, a net change of +5 holders.
- The largest Outlook Therapeutics buyer in Q2 2023 was BlackRock, an estimated $1.57M added.
- The largest Outlook Therapeutics seller in Q2 2023 was Millennium Management, an estimated $507K sold.
Based on aggregated 13F filings for Q2 2023.